Platelet reactivity in dyslipidemia: atherothrombotic signaling and therapeutic implications

Area of Science:

• Cardiovascular Biology
• Hematology
• Metabolic Disorders

Background:

• Dyslipidemia and metabolic disorders significantly elevate risks for thrombotic events like myocardial infarction, stroke, and deep vein thrombosis, contributing to global mortality.
• Platelets in a pre-activated state are a key mediator of increased thrombotic risk in dyslipidemia.
• Platelet hyperreactivity involves classic receptor signaling and pattern recognition receptor sensitization, alongside elevated platelet counts due to hematopoietic dysregulation.

Purpose of the Study:

• To review the multifaceted mechanisms of platelet activation and sensitization in dyslipidemia.
• To explore how these platelet alterations contribute to a prothrombotic phenotype.
• To discuss potential novel antithrombotic therapeutic strategies targeting platelet signaling in dyslipidemia.

Main Methods:

• Literature review of recent evidence on platelet function in dyslipidemia.
• Analysis of signaling pathways involved in platelet activation and sensitization.
• Overview of factors contributing to elevated platelet counts.

Main Results:

• Dyslipidemia is associated with platelets in a pre-activated state, increasing thrombotic risk.
• Multiple mechanisms, including receptor signaling and pattern recognition receptors, enhance platelet reactivity.
• Dysregulated hematopoiesis leads to elevated platelet counts, further promoting thrombosis.

Conclusions:

• Current antiplatelet and anticoagulation therapies have limitations in preventing recurrent thrombotic events.
• A deeper understanding of platelet pathophysiology in dyslipidemia is crucial for revising antithrombotic approaches.
• Targeting specific platelet signaling mechanisms offers promising avenues for novel antithrombotic therapies.